| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1997;96:2385-2396.)
© 1997 American Heart Association, Inc.
Articles |
Modulation of the Renin-Angiotensin Pathway Through Enzyme Inhibition and Specific Receptor Blockade in Pacing-Induced Heart Failure
I. Effects on Left Ventricular Performance and Neurohormonal Systems
From the Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, and the Pharmaceutical Division, Novartis, Basel, Switzerland (M. de G., S.W.)
Correspondence to Francis G. Spinale, MD, PhD, Cardiothoracic Surgery and Physiology, Medical University of South Carolina, Charleston, SC 29425.
Background The goal of this study was to determine the effects of ACE inhibition (ACEI) alone, AT1 angiotensin (Ang) II receptor blockade alone, and combined ACEI and AT1 Ang II receptor blockade on LV function, systemic hemodynamics, and neurohormonal system activity in a model of congestive heart failure (CHF).
Methods and Results Pigs were randomly assigned to each of 5 groups: (1) rapid atrial pacing (240 bpm) for 3 weeks (n=9), (2) ACEI (benazeprilat, 0.187 mg · kg-1 · d-1) and rapid pacing (n=9), (3) AT1 Ang II receptor blockade (valsartan, 3 mg · kg-1 · d-1) and rapid pacing (n=9), (4) ACEI and AT1 Ang II receptor blockade (benazeprilat/valsartan, 0.05/3 mg · kg-1 · d-1) and rapid pacing (n=9), and (5) sham controls (n=10). In the pacing group, LV fractional shortening (LVFS) fell (13.4±1.4% versus 39.1±1.0%) and end-diastolic dimension (LVEDD) increased (5.61±0.11 versus 3.45±0.07 cm) compared with control (P<.05). With AT1 Ang II blockade and rapid pacing, LVEDD and LVFS were unchanged from pacing-only values. ACEI reduced LVEDD (4.95±0.11 cm) and increased LVFS (20.9±1.9%) from pacing-only values (P<.05). ACEI and AT1 Ang II blockade reduced LVEDD (4.68±0.07 cm) and increased LVFS (25.2±0.9%) from pacing only (P<.05). Plasma norepinephrine and endothelin increased by more than fivefold with chronic pacing and remained elevated with AT1 Ang II blockade. Plasma norepinephrine was reduced from pacing-only values by more than twofold in the ACEI group and the combination group. ACEI and AT1 Ang II receptor blockade reduced plasma endothelin levels by >50% from rapid-pacing values.
Conclusions These findings suggest that the effects of ACEI in the setting of CHF are not solely due to modulation of Ang II levels but rather to alternative enzymatic pathways and that combined ACEI and AT1 Ang II receptor blockade may provide unique benefits for LV pump function and neurohormonal systems in the setting of CHF.
Key Words: myocardium • heart failure • angiotensin • cardiovascular disease
This article has been cited by other articles:
 |
|
 |
|
  C.-P. Cheng, H.-J. Cheng, C. Cunningham, Z. K. Shihabi, D. C. Sane, T. Wannenburg, and W. C. Little Angiotensin II Type 1 Receptor Blockade Prevents Alcoholic Cardiomyopathy Circulation, July 18, 2006; 114(3): 226 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Deschamps, K. A. Apple, A. H. Leonardi, J. E. McLean, W. M. Yarbrough, R. E. Stroud, L. L. Clark, J. A. Sample, and F. G. Spinale Myocardial Interstitial Matrix Metalloproteinase Activity Is Altered by Mechanical Changes in LV Load: Interaction With the Angiotensin Type 1 Receptor Circ. Res., May 27, 2005; 96(10): 1110 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Funabiki, K. Onishi, K. Dohi, T. Koji, K. Imanaka-Yoshida, M. Ito, H. Wada, N. Isaka, T. Nobori, and T. Nakano Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2487 - H2492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ohta, N. Hasebe, S. Tsuji, K. Izawa, Y.-T. Jin, S. Kido, S. Natori, M. Sato, and K. Kikuchi Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2914 - H2921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. McCurley, S. U. Hanlon, S.-k. Wei, E. F. Wedam, M. Michalski, and M. C. Haigney Furosemide and the progression of left ventricular dysfunction in experimental heart failure J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1301 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Azizi and J. Menard Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists Circulation, June 1, 2004; 109(21): 2492 - 2499. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yoshida, K. Yamamoto, T. Mano, Y. Sakata, N. Nishikawa, M. Nishio, T. Ohtani, T. Miwa, M. Hori, and T. Masuyama AT1 Receptor Blocker Added to ACE Inhibitor Provides Benefits at Advanced Stage of Hypertensive Diastolic Heart Failure Hypertension, March 1, 2004; 43(3): 686 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Okuda, M. Yano, M. Doi, T. Oda, T. Tokuhisa, M. Kohno, S. Kobayashi, T. Yamamoto, T. Ohkusa, and M. Matsuzaki Valsartan Restores Sarcoplasmic Reticulum Function With No Appreciable Effect on Resting Cardiac Function in Pacing-Induced Heart Failure Circulation, February 24, 2004; 109(7): 911 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sato, H. Yaoita, K. Maehara, and Y. Maruyama Attenuation of heart failure due to coronary stenosis by ACE inhibitor and angiotensin receptor blocker Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H359 - H368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xu, D. Kumar, J. R. B. Dyck, W. R. Ford, A. S. Clanachan, G. D. Lopaschuk, and B. I. Jugdutt AT1 and AT2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1206 - H1215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Multani, R. S. Krombach, A. T. Goldberg, M. K. King, J. W. Hendrick, J. A. Sample, S. C. Baicu, C. Joffs, M. deGasparo, and F. G. Spinale Myocardial Bradykinin Following Acute Angiotensin-Converting Enzyme Inhibition, AT1 Receptor Blockade, or Combined Inhibition in Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 369 - 376. [Abstract] [PDF]
|
|
|
|
 |
|
 D. B Haitsma, D. Bac, N. Raja, F. Boomsma, P. D Verdouw, and D. J Duncker Minimal impairment of myocardial blood flow responses to exercise in the remodeled left ventricle early after myocardial infarction, despite significant hemodynamic and neurohumoral alterations Cardiovasc Res, December 1, 2001; 52(3): 417 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Joffs, C. A. Walker, J. W. Hendrick, D. J. Fary, D. K. Almany, J. N. Davis, A. T. Goldberg, F. A. Crawford Jr, and F. G. Spinale Endothelin receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., August 1, 2001; 122(2): 365 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Coker, J. R. Jolly, C. Joffs, T. Etoh, J. R. Holder, B. R. Bond, and F. G. Spinale Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation Am J Physiol Heart Circ Physiol, August 1, 2001; 281(2): H543 - H551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Siragy, M. de Gasparo, M. El-Kersh, and R. M. Carey Angiotensin-Converting Enzyme Inhibition Potentiates Angiotensin II Type 1 Receptor Effects on Renal Bradykinin and cGMP Hypertension, August 1, 2001; 38(2): 183 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mankad, T. A. d'Amato, N. Reichek, W. E. McGregor, J. Lin, D. Singh, W. J. Rogers, and C. M. Kramer Combined Angiotensin II Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition Further Attenuates Postinfarction Left Ventricular Remodeling Circulation, June 12, 2001; 103(23): 2845 - 2850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Sironi, A. M. Calvio, L. Arnaboldi, A. Corsini, A. Parolari, M. de Gasparo, E. Tremoli, and L. Mussoni Effect of Valsartan on Angiotensin II-Induced Plasminogen Activator Inhibitor-1 Biosynthesis in Arterial Smooth Muscle Cells Hypertension, March 1, 2001; 37(3): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. King, D. M. Gay, L. C. Pan, J. H. McElmurray III, J. W. Hendrick, C. Pirie, A. Morrison, C. Ding, R. Mukherjee, and F. G. Spinale Treatment With a Growth Hormone Secretagogue in a Model of Developing Heart Failure : Effects on Ventricular and Myocyte Function Circulation, January 16, 2001; 103(2): 308 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kim, M. Yoshiyama, Y. Izumi, H. Kawano, M. Kimoto, Y. Zhan, and H. Iwao Effects of Combination of ACE Inhibitor and Angiotensin Receptor Blocker on Cardiac Remodeling, Cardiac Function, and Survival in Rat Heart Failure Circulation, January 2, 2001; 103(1): 148 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-G. Xia, O. Chung, H. Spitznagel, S. Illner, G. Janichen, B. Rossius, P. Gohlke, and T. Unger Significance of timing of angiotensin AT1 receptor blockade in rats with myocardial infarction-induced heart failure Cardiovasc Res, January 1, 2001; 49(1): 110 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kawai, S. Y. Stevens, and C.-S. Liang Renin-angiotensin system inhibition on noradrenergic nerve terminal function in pacing-induced heart failure Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H3012 - H3019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. van Kats, D. J. Duncker, D. B. Haitsma, M. P. Schuijt, R. Niebuur, R. Stubenitsky, F. Boomsma, M. A. D. H. Schalekamp, P. D. Verdouw, and A. H. J. Danser Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Blockade Prevent Cardiac Remodeling in Pigs After Myocardial Infarction : Role of Tissue Angiotensin II Circulation, September 26, 2000; 102(13): 1556 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. New, A. C. Sampson, M. K. King, J. W. Hendrick, M. J. Clair, J. H. McElmurray III, J. Mandel, R. Mukherjee, Marc de Gasparo, and F. G. Spinale Effects of Combined Angiotensin II and Endothelin Receptor Blockade With Developing Heart Failure : Effects on Left Ventricular Performance Circulation, September 19, 2000; 102(12): 1447 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Grossman, F. H. Messerli, and J. M. Neutel Angiotensin II Receptor Blockers: Equal or Preferred Substitutes for ACE Inhibitors? Arch Intern Med, July 10, 2000; 160(13): 1905 - 1911. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Clair, M. K. King, A. T. Goldberg, J. W. Hendrick, R. Nisato, D. M. Gay, A. E. Morrison, J. H. McElmurray III, R. S. Krombach, B. R. Bond, et al. Selective Vasopressin, Angiotensin II, or Dual Receptor Blockade with Developing Congestive Heart Failure J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 852 - 860. [Abstract] [Full Text]
|
|
|
|
|
|
K. Yamamoto, T. Masuyama, Y. Sakata, R. Doi, K. Ono, T. Mano, H. Kondo, T. Kuzuya, T. Miwa, and M. Hori Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and 'overdrive' of the endothelin system Cardiovasc Res, June 1, 2000; 46(3): 421 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G Spinale, M. L Coker, B. R Bond, and J. L Zellner Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target Cardiovasc Res, May 1, 2000; 46(2): 225 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chen, Q. Shi, and S. M. Scharf Hemodynamic effects of periodic obstructive apneas in sedated pigs with congestive heart failure J Appl Physiol, March 1, 2000; 88(3): 1051 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A.M. Zornoff, S. A.R. Paiva, B. B. Matsubara, L. S. Matsubara, and J. Spadaro Combination Therapy with Angiotensin Converting Enzyme Inhibition and AT1 Receptor Inhibitor on Ventricular Remodeling After Myocardial Infarction in Rats Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 203 - 209. [Abstract] [PDF]
|
|
|
|
|
|
R. S. Krombach, J. H. McElmuray, D. M. Gay, M. J. Clair, R. Mukherjee, A. T. Goldberg, S. C. Baicu, and F. G. Spinale Bradykinin Degradation and Relation to Myocyte Contractility Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 291 - 299. [Abstract] [PDF]
|
|
|
|
|
|
J. H. McElmurray III, R. Mukherjee, R. B. New, A. C. Sampson, M. K. King, J. W. Hendrick, A. Goldberg, T. J. Peterson, H. Hallak, M. R. Zile, et al. Angiotensin-Converting Enzyme and Matrix Metalloproteinase Inhibition with Developing Heart Failure: Comparative Effects on Left Ventricular Function and Geometry J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 799 - 811. [Abstract] [Full Text]
|
|
|
|
|
|
R. S. McKelvie, S. Yusuf, D. Pericak, A. Avezum, R. J. Burns, J. Probstfield, R. T. Tsuyuki, M. White, J. Rouleau, R. Latini, et al. Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure : Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RESOLVD Pilot Study Investigators Circulation, September 7, 1999; 100(10): 1056 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tanimura, V. G. Sharov, H. Shimoyama, T. Mishima, T. B. Levine, S. Goldstein, and H. N. Sabbah Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure Am J Physiol Heart Circ Physiol, April 1, 1999; 276(4): H1385 - H1392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Saad, R. Mukherjee, P. B. Thomas, J. P. Iannini, C. G. Basler, L. Hebbar, S.-J. O, S. Moreland, M. L. Webb, J. R. Powell, et al. The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1779 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jalowy, R. Schulz, H. Dorge, M. Behrends, and G. Heusch Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1787 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Spinale, R. Mukherjee, R. S. Krombach, M. J. Clair, J. W. Hendrick, W. V. Houck, L. Hebbar, S. B. Kribbs, J. L. Zellner, and M. G. Dodd Chronic Amlodipine Treatment During the Development of Heart Failure Circulation, October 20, 1998; 98(16): 1666 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Stein, F. G. Spinale, R. Mukherjee, J. P. Iannini, L. Hebbar, M. J. Clair, D. M. Melton, S. Krombach, M. H. Cox, P. B. Thomas, et al. ACE Inhibition and Heart Failure • Response Circulation, July 28, 1998; 98(4): 380 - 381. [Full Text]
|
|
|
|
|
|
R.S. Krombach, M. J Clair, J. W Hendrick, W. V Houck, J. L Zellner, S. B Kribbs, S. Whitebread, R. Mukherjee, M. de Gasparo, and F. G Spinale Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns Cardiovasc Res, June 1, 1998; 38(3): 631 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Spinale, R. Mukherjee, J. P. Iannini, S. Whitebread, L. Hebbar, M. J. Clair, D. M. Melton, M. H. Cox, P. B. Thomas, and P. B. Marc de Gasparo Modulation of the Renin-Angiotensin Pathway Through Enzyme Inhibition and Specific Receptor Blockade in Pacing-Induced Heart Failure : II. Effects on Myocyte Contractile Processes Circulation, October 7, 1997; 96(7): 2397 - 2406. [Abstract] [Full Text]
|
|
|
|
|
|
D. B. Haitsma, D. Merkus, J. Vermeulen, P. D. Verdouw, and D. J. Duncker Nitric oxide production is maintained in exercising swine with chronic left ventricular dysfunction Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2198 - H2209. [Abstract] [Full Text] [PDF]
|
|